Short communicationPublished 25 Jun 2021

TMACâ?¢: A novel Affimer® drug conjugate platform to modulate the TME.

Authors: Amrik Basran

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The Affimer platform is an antibody mimetic scaffold based on the human protease inhibitor, Stefin A and we have generated a range of antagonists against several key checkpoints such PD-L1. With our anti-PDL1 Affimer Fc we have demonstrated total tumour regression in mouse syngeneic models in combination with Talabostat and immunity to rechallenge with tumour cells, showing that we have achieved an immune memory response. Conjugating Talabostat to an Affimer antagonist using a novel FAP-alpha cleavable linker (TMAC™), we have demonstrated tolerability and efficacy in mouse syngeneic models.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalResearch Journal of Nervous System
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Amrik Basran”